Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study
BackgroundThe availability of pharmacogenomic (PGx) methods to determine the right drug and dosage for individualized patient treatment has increased over the past decade. Adoption of the resulting PGx reports in a clinical setting and monitoring of clinical outcomes is a cha...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
JMIR Publications
2022-05-01
|
| Series: | JMIRx Med |
| Online Access: | https://med.jmirx.org/2022/2/e32902 |
| _version_ | 1797329416768978944 |
|---|---|
| author | Christian Tagwerker Mary Jane Carias-Marines David J Smith |
| author_facet | Christian Tagwerker Mary Jane Carias-Marines David J Smith |
| author_sort | Christian Tagwerker |
| collection | DOAJ |
| description |
BackgroundThe availability of pharmacogenomic (PGx) methods to determine the right drug and dosage for individualized patient treatment has increased over the past decade. Adoption of the resulting PGx reports in a clinical setting and monitoring of clinical outcomes is a challenging and long-term commitment.
ObjectiveThis study summarizes an extended PGx deep sequencing panel intended for medication dosing and prescription guidance newly adopted in a pain management clinic. The primary outcome of this retrospective study reports the number of cases and types of drugs covered, for which PGx data appears to have assisted in optimal drug prescription and dosing.
MethodsA PGx panel is described, encompassing 23 genes and 141 single-nucleotide polymorphisms or indels, combined with PGx dosing guidance and drug-gene interaction (DGI) and drug-drug interaction (DDI) reporting to prevent adverse drug reactions (ADRs). During a 2-year period, patients (N=171) were monitored in a pain management clinic. Urine toxicology, PGx reports, and progress notes were studied retrospectively for changes in prescription regimens before and after the PGx report was made available to the provider. An additional algorithm provided DGIs and DDIs to prevent ADRs.
ResultsAmong patient PGx reports with medication lists provided (n=146), 57.5% (n=84) showed one or more moderate and 5.5% (n=8) at least one serious PGx interaction. A total of 96 (65.8%) patients showed at least one moderate and 15.1% (n=22) one or more serious DGIs or DDIs. A significant number of active changes in prescriptions based on the 102 PGx/DGI/DDI report results provided was observed for 85 (83.3%) patients for which a specific drug was either discontinued or switched within the defined drug classes of the report, or a new drug was added.
ConclusionsPreventative action was observed for all serious interactions, and only moderate interactions were tolerated for the lack of other alternatives. This study demonstrates the application of an extended PGx panel combined with a customized informational report to prevent ADRs and improve patient care. |
| first_indexed | 2024-03-08T07:04:20Z |
| format | Article |
| id | doaj.art-101c440ad0fc40fb94b963bd49dc05ce |
| institution | Directory Open Access Journal |
| issn | 2563-6316 |
| language | English |
| last_indexed | 2024-03-08T07:04:20Z |
| publishDate | 2022-05-01 |
| publisher | JMIR Publications |
| record_format | Article |
| series | JMIRx Med |
| spelling | doaj.art-101c440ad0fc40fb94b963bd49dc05ce2024-02-03T04:55:12ZengJMIR PublicationsJMIRx Med2563-63162022-05-0132e3290210.2196/32902Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective StudyChristian Tagwerkerhttps://orcid.org/0000-0002-5699-0037Mary Jane Carias-Marineshttps://orcid.org/0000-0002-1131-7914David J Smithhttps://orcid.org/0000-0002-9460-6227 BackgroundThe availability of pharmacogenomic (PGx) methods to determine the right drug and dosage for individualized patient treatment has increased over the past decade. Adoption of the resulting PGx reports in a clinical setting and monitoring of clinical outcomes is a challenging and long-term commitment. ObjectiveThis study summarizes an extended PGx deep sequencing panel intended for medication dosing and prescription guidance newly adopted in a pain management clinic. The primary outcome of this retrospective study reports the number of cases and types of drugs covered, for which PGx data appears to have assisted in optimal drug prescription and dosing. MethodsA PGx panel is described, encompassing 23 genes and 141 single-nucleotide polymorphisms or indels, combined with PGx dosing guidance and drug-gene interaction (DGI) and drug-drug interaction (DDI) reporting to prevent adverse drug reactions (ADRs). During a 2-year period, patients (N=171) were monitored in a pain management clinic. Urine toxicology, PGx reports, and progress notes were studied retrospectively for changes in prescription regimens before and after the PGx report was made available to the provider. An additional algorithm provided DGIs and DDIs to prevent ADRs. ResultsAmong patient PGx reports with medication lists provided (n=146), 57.5% (n=84) showed one or more moderate and 5.5% (n=8) at least one serious PGx interaction. A total of 96 (65.8%) patients showed at least one moderate and 15.1% (n=22) one or more serious DGIs or DDIs. A significant number of active changes in prescriptions based on the 102 PGx/DGI/DDI report results provided was observed for 85 (83.3%) patients for which a specific drug was either discontinued or switched within the defined drug classes of the report, or a new drug was added. ConclusionsPreventative action was observed for all serious interactions, and only moderate interactions were tolerated for the lack of other alternatives. This study demonstrates the application of an extended PGx panel combined with a customized informational report to prevent ADRs and improve patient care.https://med.jmirx.org/2022/2/e32902 |
| spellingShingle | Christian Tagwerker Mary Jane Carias-Marines David J Smith Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study JMIRx Med |
| title | Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study |
| title_full | Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study |
| title_fullStr | Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study |
| title_full_unstemmed | Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study |
| title_short | Effects of Pharmacogenomic Testing in Clinical Pain Management: Retrospective Study |
| title_sort | effects of pharmacogenomic testing in clinical pain management retrospective study |
| url | https://med.jmirx.org/2022/2/e32902 |
| work_keys_str_mv | AT christiantagwerker effectsofpharmacogenomictestinginclinicalpainmanagementretrospectivestudy AT maryjanecariasmarines effectsofpharmacogenomictestinginclinicalpainmanagementretrospectivestudy AT davidjsmith effectsofpharmacogenomictestinginclinicalpainmanagementretrospectivestudy |